NO990560D0 - Kjemisk modifiserte polypeptider - Google Patents

Kjemisk modifiserte polypeptider

Info

Publication number
NO990560D0
NO990560D0 NO990560A NO990560A NO990560D0 NO 990560 D0 NO990560 D0 NO 990560D0 NO 990560 A NO990560 A NO 990560A NO 990560 A NO990560 A NO 990560A NO 990560 D0 NO990560 D0 NO 990560D0
Authority
NO
Norway
Prior art keywords
modified polypeptide
chemically modified
modified polypeptides
polypeptide
modified
Prior art date
Application number
NO990560A
Other languages
English (en)
Other versions
NO990560L (no
NO322978B1 (no
Inventor
Motoo Yamasaki
Toshiyuki Suzawa
Ken Kobayashi
Noboru Konishi
Shiro Akinaga
Kumiko Maruyama
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO990560D0 publication Critical patent/NO990560D0/no
Publication of NO990560L publication Critical patent/NO990560L/no
Publication of NO322978B1 publication Critical patent/NO322978B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19990560A 1997-06-06 1999-02-05 Kjemisk modifisert polypeptid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat. NO322978B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14934297 1997-06-06
PCT/JP1998/002504 WO1998055500A1 (fr) 1997-06-06 1998-06-05 Polypeptides chimiquement modifies

Publications (3)

Publication Number Publication Date
NO990560D0 true NO990560D0 (no) 1999-02-05
NO990560L NO990560L (no) 1999-03-26
NO322978B1 NO322978B1 (no) 2006-12-18

Family

ID=15473025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990560A NO322978B1 (no) 1997-06-06 1999-02-05 Kjemisk modifisert polypeptid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat.

Country Status (15)

Country Link
US (2) US6583267B2 (no)
EP (1) EP0921131B1 (no)
JP (1) JP4011124B2 (no)
KR (1) KR100565022B1 (no)
CN (1) CN1250566C (no)
AT (1) ATE469166T1 (no)
AU (1) AU744085B2 (no)
CA (1) CA2263795C (no)
DE (1) DE69841682D1 (no)
HK (1) HK1022919A1 (no)
HU (1) HUP0001153A3 (no)
NO (1) NO322978B1 (no)
NZ (1) NZ334068A (no)
RO (1) RO121474B1 (no)
WO (1) WO1998055500A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2263795C (en) * 1997-06-06 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
AU2002325819B2 (en) 2001-07-11 2008-06-19 Maxygen, Inc. G-CSF Conjugates
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
CA2607844C (en) 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
EP2339014B1 (en) 2005-11-16 2015-05-27 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US20090252720A1 (en) 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
NZ574721A (en) 2006-09-08 2012-02-24 Ambrx Inc Hybrid suppressor trna for vertebrate cells
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
RS53404B (en) 2007-08-27 2014-10-31 Ratiopharm Gmbh LIQUID FORMULATION OF G-CSF CONJUGATES
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP3584255B1 (en) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
BR112021015832A2 (pt) 2019-02-12 2022-01-18 Ambrx Inc Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
JPH0644927B2 (ja) * 1987-03-14 1994-06-15 日本油脂株式会社 徐放性活性成分放出剤
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH0796558B2 (ja) 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP2931622B2 (ja) * 1989-05-27 1999-08-09 住友製薬株式会社 ポリエチレングリコール誘導体を得る製造方法
ATE136315T1 (de) 1989-05-27 1996-04-15 Sumitomo Pharma Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine.
JPH03236400A (ja) * 1990-02-09 1991-10-22 Kirin Brewery Co Ltd 化学修飾ポリペプチド及びその用途
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JPH06319537A (ja) 1993-05-18 1994-11-22 Daikin Ind Ltd 修飾ペプチドおよびその製造方法
AU711535B2 (en) 1994-02-23 1999-10-14 Kyowa Hakko Kirin Co., Ltd. Platelet growth accelerator
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6884419B1 (en) 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
CA2263795C (en) 1997-06-06 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
ES2242396T3 (es) * 1998-04-28 2005-11-01 Applied Research Systems Ars Holding N.V. Conjugados de analogos de peg-lhrh.

Also Published As

Publication number Publication date
WO1998055500A1 (fr) 1998-12-10
NO990560L (no) 1999-03-26
RO121474B1 (ro) 2007-06-29
KR100565022B1 (ko) 2006-03-30
EP0921131A4 (en) 2002-11-27
NZ334068A (en) 2000-07-28
JP4011124B2 (ja) 2007-11-21
DE69841682D1 (de) 2010-07-08
KR20000068069A (ko) 2000-11-25
US6583267B2 (en) 2003-06-24
CN1236370A (zh) 1999-11-24
AU7551298A (en) 1998-12-21
HK1022919A1 (en) 2000-11-03
HUP0001153A2 (hu) 2000-10-28
CA2263795C (en) 2008-02-19
AU744085B2 (en) 2002-02-14
ATE469166T1 (de) 2010-06-15
EP0921131A1 (en) 1999-06-09
US20030195339A1 (en) 2003-10-16
HUP0001153A3 (en) 2000-12-28
US7547675B2 (en) 2009-06-16
US20020028912A1 (en) 2002-03-07
EP0921131B1 (en) 2010-05-26
CA2263795A1 (en) 1998-12-10
CN1250566C (zh) 2006-04-12
NO322978B1 (no) 2006-12-18

Similar Documents

Publication Publication Date Title
NO990560D0 (no) Kjemisk modifiserte polypeptider
PT96068A (pt) Processo para a producao de proteina biologicamente activa
ES2063278T3 (es) Proteina morfogenetica de hueso.
EE200700058A (et) Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
DE69533556D1 (de) N-terminal modifizierte Polypeptide, und Herstellungsprozess
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
PT877716E (pt) Composicoes de vidro bioactivo para uso no tratamento de estruturas dentais
ATE173478T1 (de) Varianten des pankreatischen rinder- trypsininhibitors, deren herstellung und verwendung
PT792287E (pt) Analogos peptidicos da proteina basica da mielina humana
DE69006628D1 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin.
ATA293589A (de) Neue chinolinsulfonaminoderivate und verfahren zu deren herstellung sowie pharmazeutische zusammensetzung
ATE109793T1 (de) Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
ATE323766T1 (de) Glykosylierte leptinzusammensetzungen und zugehörige verfahren
DE69520475T2 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
ATE346096T1 (de) G-csf tpo fusionsproteine
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ATA234689A (de) Neue 2-carbonyl substituierte n,n'-di(trimethoxybenzoyl)piperazine, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
PT83688B (pt) Processo de preparacao de uma molecula de adn, de um polipeptido e de composicao farmaceutica contendo-o
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
CA2247998A1 (en) Fragments of cr1 and their use
BR9612675A (pt) Polipeptídeo ou composicão de polipeptídeo composicão imunogenica adequada para admistracão por injecao e uso de polipeptideo ou de composicão imunogenica
WO1994015962A3 (en) Derivatized calcitonins
BR8902460A (pt) Processo para preparacao de hidrolisado de proteina de baixa imunogenicidade e antigenicidade,para uso enteral
ATA166890A (de) Rekombinantes dna-molekül für allergene des erlenpollens, damit hergestellte proteine bzw. polypeptide, sowie deren anwendung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees